Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case

BACKGROUND: BRAF and MEK are component of the MAPK/ERK pathway and inhibitors of these proteins have significantly improved the outcome of metastatic melanoma. We report for the first time two sequential episodes of pneumonitis presumably induced by trametinib (a MEK inhibitor) and vemurafenib (a BR...

Descripción completa

Detalles Bibliográficos
Autores principales: Giraud, Violaine, Longvert, Christine, Houlle-Crepin, Solène, Danel, Claire, Labrune, Sylvie, Camus, Philippe, Saiag, Philippe, Chinet, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612419/
https://www.ncbi.nlm.nih.gov/pubmed/26481107
http://dx.doi.org/10.1186/s12885-015-1754-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612419/
https://www.ncbi.nlm.nih.gov/pubmed/26481107
http://dx.doi.org/10.1186/s12885-015-1754-3

Ejemplares similares